Literature DB >> 18702666

Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers.

Francisco J Gonzalez-Velasquez1, Joseph A Kotarek, Melissa A Moss.   

Abstract

Cerebral amyloid angiopathy associated with Alzheimer's disease is characterized by cerebrovascular deposition of the amyloid-beta protein (Abeta). Abeta elicits a number of morphological and biochemical alterations in the cerebral microvasculature, which culminate in hemorrhagic stroke. Among these changes, compromise of the blood-brain barrier has been described in Alzheimer's disease brain, transgenic animal models of Alzheimer's disease, and cell culture experiments. In the current study, presented data illustrates that isolated soluble Abeta(1-40) aggregates, but not unaggregated monomer or mature fibril, enhance permeability in human brain microvascular endothelial monolayers. Abeta(1-40)-induced changes in permeability are paralleled by both a decrease in transendothelial electrical resistance and a re-localization of the tight junction-associated protein zonula occludin-1 away from cell borders and into the cytoplasm. Small soluble Abeta(1-40) aggregates are confirmed to be the most potent stimulators of endothelial monolayer permeability by establishing an inverse relationship between average aggregate size and stimulated changes in diffusional permeability coefficients. These results support previous findings demonstrating that small soluble Abeta(1-40) aggregates are also primarily responsible for endothelial activation, suggesting that these same species may elicit other changes in the cerebrovasculature associated with cerebral amyloid angiopathy and Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702666      PMCID: PMC4406342          DOI: 10.1111/j.1471-4159.2008.05618.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  69 in total

Review 1.  A vascular connection to Alzheimer's disease.

Authors:  J A Rhodin; T Thomas
Journal:  Microcirculation       Date:  2001-08       Impact factor: 2.628

2.  Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease.

Authors:  H M Wisniewski; A W Vorbrodt; J Wegiel
Journal:  Ann N Y Acad Sci       Date:  1997-09-26       Impact factor: 5.691

3.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

4.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

Authors:  Igor Klyubin; Dominic M Walsh; Cynthia A Lemere; William K Cullen; Ganesh M Shankar; Vicki Betts; Edward T Spooner; Liying Jiang; Roger Anwyl; Dennis J Selkoe; Michael J Rowan
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

Review 5.  Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply.

Authors:  Craig S Atwood; Richard L Bowen; Mark A Smith; George Perry
Journal:  Brain Res Brain Res Rev       Date:  2003-09

6.  Effects of beta-amyloid on rat neuromicrovascular endothelial cells cultured in vitro.

Authors:  Marcella Folin; Silvia Baiguera; Mara Tommasini; Diego Guidolin; Maria Teresa Conconi; Eugenio De Carlo; Gastone G Nussdorfer; Pier Paolo Parnigotto
Journal:  Int J Mol Med       Date:  2005-06       Impact factor: 4.101

7.  Beta-amyloid peptide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain.

Authors:  Ibolya G Farkas; Andrea Czigner; Eszter Farkas; Endre Dobó; Katalin Soós; Botond Penke; Valéria Endrész; András Mihály
Journal:  Acta Histochem       Date:  2003       Impact factor: 2.479

8.  Potentiation of beta-amyloid polymerisation by low-density lipoprotein enhances the peptide's vasoactivity.

Authors:  Lee Stanyer; D John Betteridge; Christopher C T Smith
Journal:  Biochim Biophys Acta       Date:  2004-01-22

Review 9.  Pathogenesis of cerebral amyloid angiopathy.

Authors:  Annemieke A M Rensink; Robert M W de Waal; Berry Kremer; Marcel M Verbeek
Journal:  Brain Res Brain Res Rev       Date:  2003-10

10.  Delayed disruption of barrier function in cultured human corneal epithelial cells induced by tumor necrosis factor-alpha in a manner dependent on NF-kappaB.

Authors:  Kazuhiro Kimura; Shinichiro Teranishi; Ken Fukuda; Koji Kawamoto; Teruo Nishida
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02       Impact factor: 4.799

View more
  26 in total

1.  Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.

Authors:  Anika M S Hartz; Björn Bauer; Emma L B Soldner; Andrea Wolf; Sandra Boy; Roland Backhaus; Ivan Mihaljevic; Ulrich Bogdahn; Hans H Klünemann; Gerhard Schuierer; Felix Schlachetzki
Journal:  Stroke       Date:  2011-11-23       Impact factor: 7.914

2.  High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity.

Authors:  Hisham Qosa; Loqman A Mohamed; Sweilem B Al Rihani; Yazan S Batarseh; Quoc-Viet Duong; Jeffrey N Keller; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

3.  Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid β Load and Related Toxicity in 5XFAD Mice.

Authors:  Yazan S Batarseh; Sonali S Bharate; Vikas Kumar; Ajay Kumar; Ram A Vishwakarma; Sandip B Bharate; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2017-05-15       Impact factor: 4.418

Review 4.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

5.  Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Dharmini C Mehta; Jennifer L Short; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2013-06-22       Impact factor: 4.200

6.  Structural transitions and oligomerization along polyalanine fibril formation pathways from computer simulations.

Authors:  Erin M Phelps; Carol K Hall
Journal:  Proteins       Date:  2012-03-13

7.  Gelsolin restores A beta-induced alterations in choroid plexus epithelium.

Authors:  Teo Vargas; Desiree Antequera; Cristina Ugalde; Carlos Spuch; Eva Carro
Journal:  J Biomed Biotechnol       Date:  2010-03-25

8.  Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model.

Authors:  Hisham Qosa; Harry LeVine; Jeffrey N Keller; Amal Kaddoumi
Journal:  Biochim Biophys Acta       Date:  2014-07-02

9.  Capillary electrophoresis for the analysis of the effect of sample preparation on early stages of Aβ1-40 aggregation.

Authors:  N Elizabeth Pryor; Melissa A Moss; Christa N Hestekin
Journal:  Electrophoresis       Date:  2014-06-05       Impact factor: 3.535

Review 10.  Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Authors:  Michelle A Erickson; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.